Saturday 17 October 2026
Export USNA’s income statement to Excel — free account
USANA Health Sciences, Inc.
USNA Consumer Defensive Packaged Foods
USANA Health Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $925.3 million, up 8.28% from fiscal 2024. In the quarter to June 2026, revenue fell 5.33%, EPS fell 323.1% and free cash flow grew 180.6%, each against the same quarter a year earlier.
15.54
0.16
+1.04%
Follow USNA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 37.17 | 35.69 | 31.31 |
+8 more quarters Free account |
P/S ratio |
0.43 | 0.35 | 0.39 | 0.55 | |
P/FCF ratio |
19.83 | 46.49 | 29.27 | 26.96 | |
P/Operating CF |
16.93 | 32.94 | (107.33) | (257.00) | |
P/B ratio |
0.75 | 0.59 | 0.68 | 0.95 | |
Price to Tangible BV |
1.35 | 1.16 | 1.39 | 2.05 | |
EV/Sales |
0.32 | 0.24 | 0.29 | 0.47 | |
EV/EBITDA |
4.37 | 3.00 | 3.52 | 5.51 | |
EV/Operating CF |
10.54 | 13.51 | 12.15 | 13.47 | |
EV/FCF |
14.68 | 32.49 | 21.84 | 22.71 | |
Quick Ratio |
1.63 | 1.47 | 1.27 | 1.22 | |
Current Ratio |
2.66 | 2.51 | 2.24 | 2.23 | |
Net Debt/EBITDA |
(9.21) | (6.88) | (11.23) | (13.47) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.27 | 1.25 | 1.24 | 1.31 | |
Operating CF/Net income |
(1.09) | 1.30 | 1.91 | 0.30 | |
Capex/Depreciation |
(0.08) | (0.27) | 0.11 | (0.33) | |
Interest Coverage |
— | 57.81 | 31.05 | 24.98 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
74.26% | 70.70% | 73.39% | 76.58% | |
Intangible Assets out of Total Assets |
0.33 | 0.36 | 0.36 | 0.39 | |
Share Based Compensation of Revenue |
1.52% | 1.38% | 1.66% | 1.67% | |
Graham Net Nets |
0.26 | 0.31 | 0.22 | 0.13 | |
Graham Number |
0.00 | 17.68 | 18.87 | 23.91 | |
Earnings Yield |
(5.67%) | 2.69% | 2.80% | 3.19% | |
Free Cash Flow Yield |
5.04% | 2.15% | 3.42% | 3.71% | |
Revenue per Share |
12.08 | 13.60 | 12.20 | 11.68 | |
Operating CF per Share |
1.26 | 0.53 | (0.18) | (0.11) | |
Capex per Share |
(0.17) | (0.14) | 0.06 | (0.17) | |
Free Cash Flow per Share |
1.09 | 0.39 | (0.12) | (0.28) | |
Cash per Share |
9.12 | 8.85 | 8.54 | 7.95 | |
Shareholders Equity per Share |
28.47 | 29.54 | 28.76 | 28.87 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
28.47 | 29.54 | 28.76 | 28.87 | |
Free Cash Flow |
20.18 | 7.16 | (2.28) | (5.16) | |
Working Capital |
175.39 | 176.99 | 159.84 | 145.40 | |
Capital Expenditures |
(3.14) | (2.60) | 1.11 | (3.20) | |
Net Current Asset Value |
104.16 | 98.82 | 78.59 | 65.55 | |
EV/EBIT |
0.00 | 6.30 | 7.25 | 10.15 | |
Capex to Sales |
0.01 | 0.01 | 0.00 | 0.02 | |
Price to Operating Income |
0.00 | 9.02 | 9.72 | 12.05 | |
| Other line items | |||||
Average Receivables |
5.25 | 8.54 | 6.52 | — | |
Average Payables |
16.67 | 15.10 | 14.62 | 11.63 | |
Average Inventory |
84.81 | 84.96 | 86.17 | 77.38 | |
Average Assets |
718.87 | 742.78 | 745.55 | 698.95 | |
Average Common Equity |
528.68 | 536.66 | 532.61 | 530.58 |
Columns are period end dates